BIND Therapeutics to Present at the Needham and Company 12th Annual Healthcare Conference
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the Needham and Company 12th Annual Healthcare Conference in New York on Wednesday, May 1, 2013 at 12:10 p.m. ET.
Help employers find you! Check out all the jobs and post your resume.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the Needham and Company 12th Annual Healthcare Conference in New York on Wednesday, May 1, 2013 at 12:10 p.m. ET.
Help employers find you! Check out all the jobs and post your resume.